The shortened infusion time of intravenous ibuprofen, part 2: A multicenter, open-label, surgical surveillance trial to evaluate safety

Tong J. Gan, Keith A Candiotti, Alparslan Turan, Asokumar Buvanendran, Beverly K. Philip, Eugene R. Viscusi, Suren Soghomonyan, Sergio D. Bergese

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose The literature and clinical data support the use of intravenous (IV) infusions of ibuprofen to control pain and reduce the opioid requirements associated with surgical pain. According to current guidelines, IV ibuprofen can be administered via a slow IV infusion performed during a 30-minute period. Although recent studies indicate that more rapid infusions may yield additional benefits for patients, the safety of such an approach needs further evaluation. The main purpose of this study was to determine the safety of single and multiple doses of IV ibuprofen (800 mg) administered over 5 to 10 minutes at the induction of anesthesia and after the surgical procedure for the treatment of postoperative pain. Methods This was a Phase IV, multicenter, open-label, clinical surveillance study. It was conducted at 21 hospitals in the United States, and 300 adult hospitalized patients undergoing surgery were enrolled. The exclusion criteria for the study were: inadequate IV access; hypersensitivity to any component of IV ibuprofen, aspirin, or related products; and any active, clinically significant bleeding. Also excluded were patients who had taken NSAIDs <6 hours before administration of IV ibuprofen; pregnant or breastfeeding female patients; and patients in the perioperative period of coronary artery bypass graft surgery. Patients received 800 mg of IV ibuprofen administered over 5 to 10 minutes preoperatively. Vital signs, adverse events, and pain scores were assessed. Findings Approximately 22% (65 of 300) of patients reported adverse events (serious and nonserious). The most common adverse event was infusion site pain (34 of 300 [11%]). No deaths were reported. Nine subjects reported serious adverse events, 8 of which occurred during the first 6 hours. All serious events reported were judged unrelated to ibuprofen. Of the 300 total patients, 2 (0.67%) discontinued the study drug due to an adverse event (1 patient discontinued the study because of infusion site pain, and 1 patient withdrew due to a hypersensitivity reaction after drug administration). Implications Our study found that IV ibuprofen infused over 5 to 10 minutes at induction of anesthesia is a safe administration option for surgical patients. ClinicalTrials.gov identifier: NCT01334957.

Original languageEnglish
Pages (from-to)368-375
Number of pages8
JournalClinical Therapeutics
Volume37
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Ibuprofen
Intravenous Infusions
Safety
Pain
Hypersensitivity
Anesthesia
Perioperative Period
Vital Signs
Non-Steroidal Anti-Inflammatory Agents
Patient Safety
Postoperative Pain
Breast Feeding
Coronary Artery Bypass
Pharmaceutical Preparations
Intravenous Administration
Opioid Analgesics
Aspirin
Guidelines
Hemorrhage
Transplants

Keywords

  • analgesics
  • ibuprofen
  • intravenous
  • nonopioid analgesics
  • NSAIDs
  • perioperative pain management
  • surgical pain

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

The shortened infusion time of intravenous ibuprofen, part 2 : A multicenter, open-label, surgical surveillance trial to evaluate safety. / Gan, Tong J.; Candiotti, Keith A; Turan, Alparslan; Buvanendran, Asokumar; Philip, Beverly K.; Viscusi, Eugene R.; Soghomonyan, Suren; Bergese, Sergio D.

In: Clinical Therapeutics, Vol. 37, No. 2, 01.02.2015, p. 368-375.

Research output: Contribution to journalArticle

Gan, Tong J. ; Candiotti, Keith A ; Turan, Alparslan ; Buvanendran, Asokumar ; Philip, Beverly K. ; Viscusi, Eugene R. ; Soghomonyan, Suren ; Bergese, Sergio D. / The shortened infusion time of intravenous ibuprofen, part 2 : A multicenter, open-label, surgical surveillance trial to evaluate safety. In: Clinical Therapeutics. 2015 ; Vol. 37, No. 2. pp. 368-375.
@article{eb4505e0c613496ba44b0ad5613dff71,
title = "The shortened infusion time of intravenous ibuprofen, part 2: A multicenter, open-label, surgical surveillance trial to evaluate safety",
abstract = "Purpose The literature and clinical data support the use of intravenous (IV) infusions of ibuprofen to control pain and reduce the opioid requirements associated with surgical pain. According to current guidelines, IV ibuprofen can be administered via a slow IV infusion performed during a 30-minute period. Although recent studies indicate that more rapid infusions may yield additional benefits for patients, the safety of such an approach needs further evaluation. The main purpose of this study was to determine the safety of single and multiple doses of IV ibuprofen (800 mg) administered over 5 to 10 minutes at the induction of anesthesia and after the surgical procedure for the treatment of postoperative pain. Methods This was a Phase IV, multicenter, open-label, clinical surveillance study. It was conducted at 21 hospitals in the United States, and 300 adult hospitalized patients undergoing surgery were enrolled. The exclusion criteria for the study were: inadequate IV access; hypersensitivity to any component of IV ibuprofen, aspirin, or related products; and any active, clinically significant bleeding. Also excluded were patients who had taken NSAIDs <6 hours before administration of IV ibuprofen; pregnant or breastfeeding female patients; and patients in the perioperative period of coronary artery bypass graft surgery. Patients received 800 mg of IV ibuprofen administered over 5 to 10 minutes preoperatively. Vital signs, adverse events, and pain scores were assessed. Findings Approximately 22{\%} (65 of 300) of patients reported adverse events (serious and nonserious). The most common adverse event was infusion site pain (34 of 300 [11{\%}]). No deaths were reported. Nine subjects reported serious adverse events, 8 of which occurred during the first 6 hours. All serious events reported were judged unrelated to ibuprofen. Of the 300 total patients, 2 (0.67{\%}) discontinued the study drug due to an adverse event (1 patient discontinued the study because of infusion site pain, and 1 patient withdrew due to a hypersensitivity reaction after drug administration). Implications Our study found that IV ibuprofen infused over 5 to 10 minutes at induction of anesthesia is a safe administration option for surgical patients. ClinicalTrials.gov identifier: NCT01334957.",
keywords = "analgesics, ibuprofen, intravenous, nonopioid analgesics, NSAIDs, perioperative pain management, surgical pain",
author = "Gan, {Tong J.} and Candiotti, {Keith A} and Alparslan Turan and Asokumar Buvanendran and Philip, {Beverly K.} and Viscusi, {Eugene R.} and Suren Soghomonyan and Bergese, {Sergio D.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.clinthera.2014.12.006",
language = "English",
volume = "37",
pages = "368--375",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "2",

}

TY - JOUR

T1 - The shortened infusion time of intravenous ibuprofen, part 2

T2 - A multicenter, open-label, surgical surveillance trial to evaluate safety

AU - Gan, Tong J.

AU - Candiotti, Keith A

AU - Turan, Alparslan

AU - Buvanendran, Asokumar

AU - Philip, Beverly K.

AU - Viscusi, Eugene R.

AU - Soghomonyan, Suren

AU - Bergese, Sergio D.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Purpose The literature and clinical data support the use of intravenous (IV) infusions of ibuprofen to control pain and reduce the opioid requirements associated with surgical pain. According to current guidelines, IV ibuprofen can be administered via a slow IV infusion performed during a 30-minute period. Although recent studies indicate that more rapid infusions may yield additional benefits for patients, the safety of such an approach needs further evaluation. The main purpose of this study was to determine the safety of single and multiple doses of IV ibuprofen (800 mg) administered over 5 to 10 minutes at the induction of anesthesia and after the surgical procedure for the treatment of postoperative pain. Methods This was a Phase IV, multicenter, open-label, clinical surveillance study. It was conducted at 21 hospitals in the United States, and 300 adult hospitalized patients undergoing surgery were enrolled. The exclusion criteria for the study were: inadequate IV access; hypersensitivity to any component of IV ibuprofen, aspirin, or related products; and any active, clinically significant bleeding. Also excluded were patients who had taken NSAIDs <6 hours before administration of IV ibuprofen; pregnant or breastfeeding female patients; and patients in the perioperative period of coronary artery bypass graft surgery. Patients received 800 mg of IV ibuprofen administered over 5 to 10 minutes preoperatively. Vital signs, adverse events, and pain scores were assessed. Findings Approximately 22% (65 of 300) of patients reported adverse events (serious and nonserious). The most common adverse event was infusion site pain (34 of 300 [11%]). No deaths were reported. Nine subjects reported serious adverse events, 8 of which occurred during the first 6 hours. All serious events reported were judged unrelated to ibuprofen. Of the 300 total patients, 2 (0.67%) discontinued the study drug due to an adverse event (1 patient discontinued the study because of infusion site pain, and 1 patient withdrew due to a hypersensitivity reaction after drug administration). Implications Our study found that IV ibuprofen infused over 5 to 10 minutes at induction of anesthesia is a safe administration option for surgical patients. ClinicalTrials.gov identifier: NCT01334957.

AB - Purpose The literature and clinical data support the use of intravenous (IV) infusions of ibuprofen to control pain and reduce the opioid requirements associated with surgical pain. According to current guidelines, IV ibuprofen can be administered via a slow IV infusion performed during a 30-minute period. Although recent studies indicate that more rapid infusions may yield additional benefits for patients, the safety of such an approach needs further evaluation. The main purpose of this study was to determine the safety of single and multiple doses of IV ibuprofen (800 mg) administered over 5 to 10 minutes at the induction of anesthesia and after the surgical procedure for the treatment of postoperative pain. Methods This was a Phase IV, multicenter, open-label, clinical surveillance study. It was conducted at 21 hospitals in the United States, and 300 adult hospitalized patients undergoing surgery were enrolled. The exclusion criteria for the study were: inadequate IV access; hypersensitivity to any component of IV ibuprofen, aspirin, or related products; and any active, clinically significant bleeding. Also excluded were patients who had taken NSAIDs <6 hours before administration of IV ibuprofen; pregnant or breastfeeding female patients; and patients in the perioperative period of coronary artery bypass graft surgery. Patients received 800 mg of IV ibuprofen administered over 5 to 10 minutes preoperatively. Vital signs, adverse events, and pain scores were assessed. Findings Approximately 22% (65 of 300) of patients reported adverse events (serious and nonserious). The most common adverse event was infusion site pain (34 of 300 [11%]). No deaths were reported. Nine subjects reported serious adverse events, 8 of which occurred during the first 6 hours. All serious events reported were judged unrelated to ibuprofen. Of the 300 total patients, 2 (0.67%) discontinued the study drug due to an adverse event (1 patient discontinued the study because of infusion site pain, and 1 patient withdrew due to a hypersensitivity reaction after drug administration). Implications Our study found that IV ibuprofen infused over 5 to 10 minutes at induction of anesthesia is a safe administration option for surgical patients. ClinicalTrials.gov identifier: NCT01334957.

KW - analgesics

KW - ibuprofen

KW - intravenous

KW - nonopioid analgesics

KW - NSAIDs

KW - perioperative pain management

KW - surgical pain

UR - http://www.scopus.com/inward/record.url?scp=84923648296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923648296&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2014.12.006

DO - 10.1016/j.clinthera.2014.12.006

M3 - Article

C2 - 25592331

AN - SCOPUS:84923648296

VL - 37

SP - 368

EP - 375

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 2

ER -